Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen, +617

The Lancet Oncology

5-Year AnalysisBreast OncologyOncologyHealth SciencesClinical Trials +8

PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging.

Joachim Drevs, Ralph Müller-Driver, Christine Wittig, +9

PubMed

PathologyTumor BiologyAngiogenesisOncologyReceptor Tyrosine Kinase +20

Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial

Judith Trotman, Sally F. Barrington, David Belada, +203

The Lancet Oncology

Lymphoid NeoplasiaEnd-of-induction Pet ResponseMedicinePrognostic ValueFollicular Lymphoma +5

HER2 Expression, Test Deviations, and Their Impact on Survival in Metastatic Gastric Cancer: Results From the Prospective Multicenter VARIANZ Study

Ivonne Haffner, Katrin Schierle, Elba Raimúndez, +16

Journal of Clinical Oncology

Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas

Nora Liebers, Johannes Duell, Donnacha Fitzgerald, +34

Blood Advances

Cell TherapyImmunologyPathologyPola BridgingImmunotherapy +17

Liposomal formulations of anticancer drugs: selectivity and effectiveness

Ulrich Massing, Stefan Fuxius

Drug Resistance Updates

Lipid PreparationMedicinal ChemistryMedicineLiposomal FormulationsAnti-cancer Agent +2

A prospective randomised phase-II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer

Lothar Bergmann, Luise Maute, Gerhard Heil, +13

European Journal of Cancer

OncologyPancreatic CancerGastrointestinal OncologyMedicineGemcitabine Versus Gemcitabine +6

Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX

Jean‐François Emile, Catherine Julié, Karine Le Malicot, +330

European Journal of Cancer

Prognostic BiomarkersGastrointestinal OncologyMedicineImmunologyColorectal Cancer +7

Community-driven development of a modified progression-free survival ratio for precision oncology

Andreas Möck, Christoph E. Heilig, Simon Kreutzfeldt, +101

ESMO Open

Resilience in cancer patients and how it correlates with demographics, psychological factors, and lifestyle

Lara Festerling, Jens Buentzel, Ludwig Fischer von Weikersthal, +10

Journal of Cancer Research and Clinical Oncology